Related Experiment Video
Updated: Oct 3, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting Mitochondrial COX-2 Enhances Chemosensitivity via Drp1-Dependent Remodeling of Mitochondrial Dynamics in
Lin Che1, Jia-Shen Wu1, Ze-Bang Du1
1State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China.
Abstract:
Mitochondria are highly dynamic organelles and undergo constant fission and fusion, which are both essential for the maintenance of cell physiological functions. Dysregulation of dynamin-related protein 1 (Drp1)-dependent mitochondrial dynamics is associated with tumorigenesis and the chemotherapeutic response in hepatocellular carcinoma (HCC). The enzyme cyclooxygenase-2 (COX-2) is overexpressed in most cancer types and correlates with a poor prognosis. However, the roles played by the translocation of mitochondrial COX-2 (mito-COX-2) and the interaction between mito-COX-2 and Drp1 in chemotherapeutic responses remain to be elucidated in the context of HCC. Bioinformatics analysis, paired HCC patient specimens, xenograft nude mice, immunofluorescence, transmission electron microscopy, molecular docking, CRISPR/Cas9 gene editing, proximity ligation assay, cytoplasmic and mitochondrial fractions, mitochondrial immunoprecipitation assay, and flow cytometry analysis were performed to evaluate the underlying mechanism of how mito-COX-2 and p-Drp1Ser616 interaction regulates the chemotherapeutic response via mitochondrial dynamics in vitro and in vivo. We found that COX-2 and Drp1 were frequently upregulated and confer a poor prognosis in HCC. We also found that the proportion of mito-COX-2 and p-Drp1Ser616 was increased in HCC cell lines. In vitro, we demonstrated that the enhanced mitochondrial translocation of COX-2 promotes its interaction with p-Drp1Ser616 via PTEN-induced putative kinase 1 (PINK1)-mediated Drp1 phosphorylation activation. This increase was associated with higher colony formation, cell proliferation, and mitochondrial fission. These findings were confirmed by knocking down COX-2 in HCC cells using CRISPR/Cas9 technology. Furthermore, inhibition of Drp1 using pharmacologic inhibitors (Mdivi-1) or RNA interference (siDNM1L) decreased mito-COX-2/p-Drp1Ser616 interaction-mediated mitochondrial fission, and increased apoptosis in HCC cells treated with platinum drugs. Moreover, inhibiting mito-COX-2 acetylation with the natural phytochemical resveratrol resulted in reducing cell proliferation and mitochondrial fission, occurring through upregulation of mitochondrial deacetylase sirtuin 3 (SIRT3), which, in turn, increased the chemosensitivity of HCC to platinum drugs in vitro and in vivo. Our results suggest that targeting interventions to PINK1-mediated mito-COX-2/p-Drp1Ser616-dependent mitochondrial dynamics increases the chemosensitivity of HCC and might help us to understand how to use the SIRT3-modulated mito-COX-2/p-Drp1Ser616 signaling axis to develop an effective clinical intervention in hepatocarcinogenesis.
Insights
Mitochondrial COX-2 and Drp1 interaction drives hepatocellular carcinoma (HCC) progression and chemoresistance. Targeting this axis via PINK1 or SIRT3 enhances HCC chemosensitivity, offering new therapeutic strategies.
Area of Science:
- Mitochondrial dynamics and cancer biology
- Hepatocellular carcinoma (HCC) pathogenesis
- Chemotherapeutic response mechanisms
Background:
- Mitochondria are crucial for cell function, with dysregulated dynamics linked to HCC and chemoresistance.
- Cyclooxygenase-2 (COX-2) overexpression in cancers correlates with poor prognosis.
- The role of mitochondrial COX-2 (mito-COX-2) and its interaction with dynamin-related protein 1 (Drp1) in HCC chemoresistance is unclear.
Purpose of the Study:
- To elucidate the mechanism of how mito-COX-2 and phosphorylated Drp1 (p-Drp1Ser616) interaction regulates mitochondrial dynamics and chemotherapeutic response in HCC.
- To investigate the roles of PTEN-induced putative kinase 1 (PINK1) and sirtuin 3 (SIRT3) in this pathway.
- To explore potential therapeutic interventions targeting this axis for improved HCC treatment.
Main Methods:
- Bioinformatics analysis, patient specimens, xenograft mice models, and various molecular and cellular assays (immunofluorescence, TEM, CRISPR/Cas9, PLA, etc.).
- Evaluation of mito-COX-2 and p-Drp1Ser616 levels and their interaction.
- Assessment of mitochondrial fission, apoptosis, and chemosensitivity following manipulation of COX-2, Drp1, PINK1, and SIRT3.
Main Results:
- Increased mito-COX-2 and p-Drp1Ser616 correlate with poor HCC prognosis and are elevated in HCC cell lines.
- PINK1-mediated Drp1 phosphorylation promotes mito-COX-2/p-Drp1Ser616 interaction, leading to mitochondrial fission, proliferation, and chemoresistance.
- Inhibition of Drp1 or targeting mito-COX-2 acetylation with resveratrol (upregulating SIRT3) enhances HCC chemosensitivity by modulating mitochondrial dynamics and apoptosis.
Conclusions:
- Targeting PINK1-mediated mito-COX-2/p-Drp1Ser616-dependent mitochondrial dynamics can increase HCC chemosensitivity.
- The SIRT3-modulated mito-COX-2/p-Drp1Ser616 signaling axis represents a potential therapeutic target for hepatocarcinogenesis.
- Interventions modulating mitochondrial dynamics offer promising strategies for improving clinical outcomes in HCC patients.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitochondrial Membranes
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...